Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Isolated organ perfusion combination therapy of cancer

A technology of combined therapy and organ perfusion, applied in cyclic peptide components, drug combinations, peptide/protein components, etc.

Inactive Publication Date: 2009-02-18
MERCK PATENT GMBH
View PDF58 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are technical and clinical limitations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Isolated organ perfusion combination therapy of cancer
  • Isolated organ perfusion combination therapy of cancer
  • Isolated organ perfusion combination therapy of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0151] Example 1: Cilengitide (= cyclic-(Arg-Gly-Asp-DPhe-NMeVal)) and the alkylating agent phenylalanine mustard in combination with or without the biologically active agent TNFα are separated by separation Synergistic Effect of Limb Perfusion in the Treatment of Syngeneic Rat Sarcoma BN175 in Soft Tissue

[0152] BN175 syngeneic soft tissue sarcoma was implanted into the hind limbs of immunocompetent rats. When the tumor reaches 500mm 3 When the volume is larger, the limb is separated and perfused with the therapeutic substance for 20 minutes. After the washout, the limb weight is reconnected to the circulation and the animal is allowed to recover.

[0153] The treatment experiment involves intraperitoneal (i.p.) bolus and perfusion period. If cilengitide ("MP") is given as a bolus (50 mg / kg), the curve is marked as "ip MP", otherwise it is marked as "noip". If cilengitide is present during the perfusion phase, it is expressed as MP, if not, it is expressed as Sham. All conditio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered together with said ligands, such as chemotherapeutic agents and / or radiation therapy, in isolated organ perfusion. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.

Description

Technical field [0001] The present invention relates to a combination therapy for the treatment of tumor and tumor metastasis, including the combined administration of an integrin ligand and a cancer co-therapeutic agent or other cancer co-therapeutic forms through isolated organ perfusion. The cancer co-therapeutic agent or other cancer co-therapeutic forms should be combined with When the integrin ligands are administered together, they have additive or synergistic effects. The cancer co-therapeutics or other forms of cancer co-therapies are, for example, chemotherapeutics, immunotherapeutics (including antibodies), radioimmunoconjugates, and immunotherapy. Cytokines and / or radiation therapy. The treatment preferably results in a synergistic potential enhancement of each treatment's respective inhibitory effects on tumor cell and tumor endothelial cell proliferation, resulting in a more effective treatment than when each component is administered alone, and is also preferably mo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P35/00
CPCA61K38/12A61K41/00A61K45/06A61P1/16A61P35/00A61P43/00A61K2300/00A61K38/17
Inventor S·戈德曼M·格雷尔T·L·M·滕哈根A·M·M·埃格蒙特
Owner MERCK PATENT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com